MedTrace Logo

Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder

NCT01189318 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-07

No results posted yet for this study

Summary

In this study, patients with major depressive disorder (MDD) who have insomnia symptom are treated with Seroquel XR in an open-label manner for a 4-week period with repeated measurements of insomnia symptoms and sleep parameters using polysomnography.

Conditions

Interventions

DRUG

Quetiapine Fumarate Extended Release

Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)

Sponsors & Collaborators

  • Ewha Womans University

    lead OTHER

Principal Investigators

  • Inkyoon Lyoo, MD, PhD, MMS · Ewha Womans University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189318 on ClinicalTrials.gov